SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors

Pharmacologic targeting of components of ERK signaling in ERK-dependent tumors is often limited by adaptive resistance, frequently mediated by feedback-activation of RTK signaling and rebound of ERK activity. Here, we show that combinatorial pharmacologic targeting of ERK signaling and the SHP2 phos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Tamer A., Adamopoulos, Christos, Karoulia, Zoi, Wu, Xuewei, Sachidanandam, Ravi, Aaronson, Stuart A., Poulikakos, Poulikos I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396678/
https://www.ncbi.nlm.nih.gov/pubmed/30605687
http://dx.doi.org/10.1016/j.celrep.2018.12.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396678/
https://www.ncbi.nlm.nih.gov/pubmed/30605687
http://dx.doi.org/10.1016/j.celrep.2018.12.013

Ejemplares similares